Nanogen Issued Patent For Key Component of NanoChip Electronic Microarray

    SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN),
 developer of advanced diagnostic products, announced today it was issued
 Patent No. 6,960,298, "Mesoporous permeation layers for use on active
 electronic matrix devices" by the U.S. Patent and Trademark Office.  The '298
 patent relates to synthetic polymer hydrogels with defined pore size that
 overlay an electrode on a substrate.  The technology, which is an integral
 component of the NanoChip(R) Electronic Microarray, provides high-performance
 characteristics on active electronic chip devices, offering a protective
 interface between the electrically active surface on the NanoChip(R) array and
 the biological test environment.
     Ion-permeable permeation layers are essential to the function of
 electronic devices such as the NanoChip(R) array, allowing the attachment and
 immobilization of nucleic acids, which can serve as probes for detecting
 nucleic acid sequences of interest, on the chip.  The permeation layer allows
 the diffusion of ions that balance the electric charge near the reaction site
 and the precise electronic control of analyte movement, both of which
 facilitate the rapid movement of nucleic acids to and from various test sites
 on the NanoChip(R).  The permeation layer also separates the attached
 biomolecules from the electrochemical environment generated immediately at the
 electrode, preventing the attached molecule's exposure to the highly reactive
 surface, which can rapidly destroy nucleic acids or other biomolecules.
     "Nanogen's electronic microarray platform includes many cutting-edge
 inventions, each of which contributes to the unique performance
 characteristics of our instrument system for molecular testing," said Howard
 C. Birndorf, Nanogen chairman and chief executive officer.  "Each patent we
 secure will further protect our investment in the development of products like
 the NanoChip(R) array."
 
     About Nanogen, Inc.
     Nanogen's advanced technologies provide researchers, clinicians and
 physicians worldwide with improved methods and tools to predict, diagnose, and
 ultimately help treat disease.  The company's products include real-time PCR
 reagents, the NanoChip(R) electronic microarray platform and a line of rapid
 diagnostic tests.  Nanogen's ten years of pioneering research involving
 nanotechnology holds the promise of miniaturization and continues to be
 supported for its potential for diagnostic and biowarfare applications.  For
 additional information please visit Nanogen's website at www.nanogen.com.
 
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof. Nanogen disclaims any intent or obligation to update these
 forward-looking statements.
 
 

SOURCE Nanogen, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.